These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10803561)

  • 1. ECVAM's in-house prevalidation/validation studies in the areas of haematotoxicity, reproductive toxicity, metabolism-mediated toxicity and epithelial barrier function.
    Prieto P
    Sci Total Environ; 2000 Mar; 247(2-3):349-54. PubMed ID: 10803561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ECVAM's response to the changing political environment for alternatives: consequences of the European Union chemicals and cosmetics policies.
    Hartung T; Bremer S; Casati S; Coecke S; Corvi R; Fortaner S; Gribaldo L; Halder M; Roi AJ; Prieto P; Sabbioni E; Worth A; Zuang V
    Altern Lab Anim; 2003 Nov; 31(5):473-81. PubMed ID: 15598174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ECVAM's research and validation activities in the fields of topical toxicity and human studies.
    Zuang V
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():119-23. PubMed ID: 12513662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future activities: ECVAM and the quality control of biologicals.
    Cussler K; Halder M; Hendriksen C
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():225-6. PubMed ID: 12513681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ECVAM's contributions to the implementation of the Three Rs in the production and quality control of biologicals.
    Halder M; Hendriksen C; Cussler K; Balls M
    Altern Lab Anim; 2002; 30(1):93-108. PubMed ID: 11827574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ECVAM's activities in validating alternative tests for skin corrosion and irritation.
    Fentem JH; Botham PA
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():61-7. PubMed ID: 12572585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ECVAM's collaborations with academia.
    Clothier R
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():175-83. PubMed ID: 12513670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ECVAM's activities on biologicals.
    Halder M; Balls M; Hendriksen C; Cussler K
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():125-8. PubMed ID: 12513663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ECVAM workshops: a critical assessment of their impact on the development, validation and acceptance of alternative methods.
    Combes RD
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():151-65. PubMed ID: 12513668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons learned from validation of in vitro toxicity test: from failure to acceptance into regulatory practice.
    Spielmann H; Liebsch M
    Toxicol In Vitro; 2001; 15(4-5):585-90. PubMed ID: 11566595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ECVAM's approach to intellectual property rights in the validation of alternative methods.
    Linge JP; Hartung T
    Altern Lab Anim; 2007 Aug; 35(4):441-6. PubMed ID: 17850189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro sensitivity of granulo-monocytic progenitors as a new toxicological cell system and endpoint in the ACuteTox Project.
    Cerrato L; Valeri A; Bueren JA; Albella B
    Toxicol Appl Pharmacol; 2009 Jul; 238(2):111-9. PubMed ID: 19442680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ECVAM and new technologies for toxicity testing.
    Bouvier d'Yvoire M; Bremer S; Casati S; Ceridono M; Coecke S; Corvi R; Eskes C; Gribaldo L; Griesinger C; Knaut H; Linge JP; Roi A; Zuang V
    Adv Exp Med Biol; 2012; 745():154-80. PubMed ID: 22437818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of ECVAM: a personal perspective.
    Balls M
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():239-41. PubMed ID: 12513683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ECVAM's activities on computer modelling and integrated testing.
    Worth AP
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():133-7. PubMed ID: 12513665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalidation of the rat CFU-GM assay for in vitro toxicology applications.
    Pessina A; Bonomi A; Cavicchini L; Albella B; Cerrato L; Parent-Massin D; Sibiril Y; Parchment R; Behrsing H; Verderio P; Pizzamiglio S; Giangreco M; Baglio C; Coccè V; Sisto F; Gribaldo L
    Altern Lab Anim; 2010 May; 38(2):105-17. PubMed ID: 20507183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods.
    Genschow E; Spielmann H; Scholz G; Seiler A; Brown N; Piersma A; Brady M; Clemann N; Huuskonen H; Paillard F; Bremer S; Becker K
    Altern Lab Anim; 2002; 30(2):151-76. PubMed ID: 11971753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of In Vitro Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop.
    Gennari A; Ban M; Braun A; Casati S; Corsini E; Dastych J; Descotes J; Hartung T; Hooghe-Peters R; House R; Pallardy M; Pieters R; Reid L; Tryphonas H; Tschirhart E; Tuschl H; Vandebriel R; Gribaldo L
    J Immunotoxicol; 2005 Apr; 2(2):61-83. PubMed ID: 18958661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ECVAM's activities in promoting the Three Rs in the quality control of biologicals.
    Halder M; Balls M; Hendriksen C; Cussler K
    Altern Lab Anim; 2004 Jun; 32 Suppl 1A():93-8. PubMed ID: 23577439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ECVAM's role in the implementation of the Three Rs concept in the field of biologicals.
    Hendriksen C; Cussler K; Halder M
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():41-6. PubMed ID: 12513650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.